Peptide drugs popular with influencers get backed by FDA panel, despite warnings from scientists

A panel of federal health advisers has recommended easing restrictions on several peptides, despite warnings from government scientists about their safety and effectiveness. These peptides, popular among wellness influencers and celebrities, include BPC-157, TB-500, and KPV. The Food and Drug Administration (FDA) was advised to allow pharmacies to produce these injectable peptides, with the panel voting 8-6 in favor, with one abstention. Although the panel’s decision is not binding, it may influence Health Secretary Robert F. Kennedy Jr., who supports peptides and aims to overturn existing FDA restrictions. The panel’s composition included individuals connected to the peptide industry, which may have influenced the vote. If the FDA follows the panel’s advice, telehealth companies are expected to increase marketing these chemicals for wellness and cosmetic purposes. The FDA typically follows such recommendations, though it is not obligated to do so. QUESTION: How might the increased availability of peptides impact public health and consumer safety?